News    |     Publications    |     Events

HFHS logo 541 with registration mark

Gamma Medica and Henry Ford Cancer Institute Announce the Availability of LumaGEM® Molecular Breast Imaging (MBI) Machine

By | news | No Comments

The first MBI machine in Michigan specifically designed for women with dense breast tissue and those that have a higher risk of breast cancer

WEST BLOOMFIELD, Mich. & SALEM, N.H.–Gamma Medica, a leader in molecular breast imaging (MBI) technology, today announced that the Henry Ford Cancer Institute has installed Gamma Medica’s LumaGEM® Molecular Breast Imaging system, which is the first MBI machine in Michigan. MBI is a proven, effective supplementary screening method to standard mammography and/or tomosynthesis (3D mammography), significantly increasing early detection of breast cancer in women.1 The new system can be found at the Henry Ford West Bloomfield Hospital where it will provide diagnostic and secondary screenings to women who have a higher risk of breast cancer and with dense breast tissue.

screen-shot-2016-12-06-at-11-19-46-am

Gamma Medica Announces Pennsylvania’s First Clinical Installation of LumaGEM® Molecular Breast Imaging System at Einstein Medical Center Philadelphia

By | news | No Comments

Secondary screening method significantly improves early cancer detection for women with dense breast tissue

SALEM, NH & PHILADELPHIA, PA –  Gamma Medica, a leader in molecular breast imaging (MBI) technology, today announced that Einstein Medical Center Philadelphia has installed Pennsylvania’s first clinical LumaGEM® Molecular Breast Imaging system. MBI is a proven, effective supplementary screening method to standard mammography and/or tomosynthesis (3D mammography), significantly increasing early detection of breast cancer in women.[1]

 

CHS_Logo_Revise_2R

Gamma Medica Announces Installation at Leading Medical Facility, Mercy Medical Center in Long Island, the First Clinical LumaGEM® Molecular Breast Imaging Technology to New York

By | news | No Comments

New secondary screening method enables early cancer detection in women with dense breast tissue

SALEM, N.H. & ROCKVILLE CENTRE, N.Y.- Gamma Medica, a leader in molecular breast imaging (MBI) technology, today announced that Mercy Medical Center a member of Catholic Health Services of Long Island has purchased and installed New York’s first clinical LumaGEM® Molecular Breast Imaging system. MBI is a secondary screening and diagnostic tool that is particularly useful for women who have dense breast tissue and women with a high risk of being diagnosed with cancer. It is a proven, effective supplementary screening method to mammography, significantly increasing early detection in women who are at a higher risk due to dense breast tissue.

HSL

Gamma Medica Expands into European Breast Imaging Market Through Partnership with Medical Supplies Distributor, Hospital Services Limited

By | news | No Comments

Salem, NH – Gamma Medica, a leader in molecular breast imaging (MBI) technology, today announced it has partnered with Hospital Services Limited (HSL), an established medical device company that distributes, installs and services radiology capital equipment and medical devices. This partnership will provide women with dense breast tissue access to Gamma Medica’s LumaGEM® Molecular Breast Imaging system in the United Kingdom, Ireland and the Channel Islands.

GMI Logo

Gamma Medica Partners With Medical Imaging, Inc. and Capital X-Ray, Inc. to Distribute LumaGEM® Molecular Breast Imaging to Women’s Breast Screening Centers

By | news | No Comments

SALEM, NH – Gamma Medica, a leader in molecular breast imaging (MBI) technology, today announced that it has partnered with Medical Imaging, Inc. and Capital X-Ray, Inc., leading providers of medical imaging equipment, to give women in Georgia, Louisiana, Alabama, Mississippi, Idaho and parts of Oregon, Montana, Wyoming and Washington State access to Gamma Medica’s LumaGEM® Molecular Breast Imaging (MBI) system.

major-hospital2

Gamma Medica, Alpha Imaging and Major Health Partners (MHP) Announce New Partnership to Provide First LumaGEM® in Indiana and First MBI at MHP Medical Center as a Secondary Breast Cancer Screening Option for Women with Dense Breast Tissue

By | news | No Comments

SHELBYVILLE, Ind. & Willoughby, Ohio & SALEM, N.H.–Gamma Medica, a leader in molecular breast imaging (MBI) technology announced today that through its collaboration with Ohio-based Alpha Imaging, Indiana-based Major Health Partners (MHP) has purchased and installed Gamma Medica’s LumaGEM Molecular Breast Imaging (MBI) system, the state’s first LumaGEM and the hospital’s first MBI. The MBI technology will be offered as a secondary screening and diagnostic tool following mammography, particularly for women with dense breast tissue. This proven imaging modality will enhance early breast cancer detection for women who face a greater risk of breast cancer.

screen-shot-2016-12-06-at-11-19-46-am

Gamma Medica Announces New Partnership with Leading Medical Facility, Einstein Medical Center Philadelphia, to Bring the First Clinical LumaGEM® Molecular Breast Imaging Technology to Pennsylvania

By | news | No Comments

SALEM, N.H. & PHILADELPHIA–Gamma Medica, a leader in molecular breast imaging (MBI) technology, today announced that Einstein Medical Center Philadelphia has committed to purchase Pennsylvania’s first clinical LumaGEM®Molecular Breast Imaging system. MBI is a secondary screening and diagnostic tool that is particularly useful for women who have dense breast tissue and women with a high risk of being diagnosed with cancer. It is a proven, effective supplementary screening method to standard mammography and/or tomosynthesis (3D mammography), significantly increasing early detection in women who are at a higher risk due to dense breast tissue.

Gamma Medica Honors Milestone Year for Groundbreaking MBI Breast Cancer Detection Solution at RSNA 2016

By | news | No Comments

2016 clinical evidence confirms that adding LumaGEM®Molecular Breast Imaging (MBI) to mammography as a secondary screening method is more than twice as effective as mammogram and ultrasound in detecting cancer for women with dense breast tissue

CHICAGO, IL – (Nov. 21, 2016) Gamma Medica, a leader in molecular breast imaging (MBI) technology, today announced several 2016 achievements for its LumaGEM Molecular Breast Imaging system at this year’s Radiological Society of North America (RSNA) annual meeting (booth #2871). Over the past year, this MBI system has grown in national prominence and expanded its user base through a major educational campaign on breast density called Be Certain and by driving irrefutable clinical results featured in a breakthrough clinical study. Read More

1329428212_0

Gamma Medica Announces New Partnership in the Fight Against Breast Cancer with Henry Ford Health System LP

By | news | No Comments

WEST BLOOMFIELD, Mich. & SALEM, N.H.–Gamma Medica, a leader in molecular breast imaging (MBI) technology, today announced that Henry Ford Health System has purchased Gamma Medica’s LumaGEM Molecular Breast Imagingsystem. The system is set to be installed by the end of 2016 at Henry Ford West Bloomfield Hospital. The MBI technology will be offered as a secondary screening and diagnostic tool following X-ray mammography, particularly for women with dense breast tissue. This proven imaging modality will help improve cancer detection in women who are at greater risk of developing breast cancer.

29321456654_c1b20f89fb_o

In Salem, Ayotte Highlights Legislative Efforts in the Fight Against Breast Cancer

By | news | No Comments

MANCHESTER, NH – On Monday, U.S. Senator Kelly Ayotte visited Gamma Medica in Salem to discuss her bipartisan efforts to protect access to mammograms for women and improve detection.  Senator Ayotte’s visit was in advance of Breast Cancer Awareness Month, which begins in October. Gamma Medica is a women’s health company focused on overcoming the limitations of mammography and other screening modalities in the early detection of breast cancer. Read More